Table 2.
Summary of FDA-approved HDAC inhibitor involved against cancer therapy.
| Epigenetic Drug | FDA Approved | Clinical Trial Phase | NCT Number | Deseas |
|---|---|---|---|---|
| SAHA | ✓ | I, II |
NCT00948688 NCT00857324 NCT00574587 |
Pancreatic cancer Multiple myeloma Breast cancer |
| TSA | ✓ | I | NCT03828926 | Relapsed or refractory Hematologic malignancies |
| VPA | ✓ | II, I, II |
NCT01900730 NCT00374075 NCT00326170 |
Breast cancer Spinal muscular atrophy Myelodysplastic syndrome Acute myelogenous leukemia |
| PXD101 | ✓ | I |
NCT01583777 NCT00421889 |
Advanced cancer Ovarian cancer |
| Panobinostat | ✓ | I, II, III |
NCT00840346 NCT01023308 |
Acute myeloblastic leukemia Multiple myeloma |
| MS-275 | ✓ | I, II, II |
NCT04708470 NCT00828854 NCT04708470 |
Cancer, solid tumor, microsatellite stable colon Cancer (MSS); ER + breast cancer Metastatic checkpoint Refractory HPV associated malignancies |